InflaRx
Update in progressIFRX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
InflaRx N.V. is a clinical-stage biopharma focused on inhibitors of the C5a inflammatory pathway, targeting autoimmune and inflammatory diseases. Its lead candidate, vilobelimab, is a first-in-class anti-C5a antibody in Phase 3 for early septic organ dysfunction. Izicopan targets C5aR and is in Phase 2a; IFX002 is a preclinical vilobelimab-based asset. Partnerships include Staidson, Catalent, and U.S. government collaborations. Founded 2007, based in Jena, Germany.
Company score
- Sentiment
- 0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.01
- Governance
- -0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationGermany
- CEOProf. Niels C. Riedemann M.D., Ph.D.
- Founded2007
- Employees65
- Websitewww.inflarx.de
Identifiers
- ISINNL0012661870
- FIGIBBG00HZ6PLC3
- CUSIPN44821101
- CIK0001708688